Firms Lack Incentive for HIV Vaccine, Expert Says
Posted on: Wednesday, 28 December 2005, 03:02 CST
WASHINGTON - In an unusually candid admission, the federal chief of AIDS research says he believes drug companies don't have an incentive to create a vaccine for HIV and are likely to wait to profit from it after the government develops one.
And that means the government has had to spend more time focusing on the processes that drug companies ordinarily follow in developing new medicines and bringing them to market.
"We had to spend some time and energy paying attention to those aspects of development because the private side isn't picking it up," Dr. Edmund Tramont testified in a deposition in a recent employment lawsuit obtained by The Associated Press.
Dr. Tramont is head of the AIDS research division of the National Institutes of Health, and he predicted in his testimony that the government will eventually create a vaccine.
He testified in July in the whistleblower case of Dr. Jonathan Fishbein.
"If we look at the vaccine, HIV vaccine, we're going to have an HIV vaccine. It's not going to be made by a company," Dr. Tramont said. "They're dropping out like flies because there's no real incentive for them to do it. We have to do it."
"They will eventually - if it works, they won't have to make that big investment. And they can make it and sell it and make a profit," he said.
An official of the group representing the country's major drug companies took sharp exception to Dr. Tramont's comments.
"That is simply not true. America's pharmaceutical research companies are firmly committed to HIV/AIDS vaccine research and development with 15 potential vaccines in development today," said Ken Johnson, the senior vice president of PhRMA, the Pharmaceutical Research and Manufacturers of America.
"Vaccine research is crucial to controlling the AIDS pandemic, and our companies are well aware of the need to succeed in this vital area of science," Mr. Johnson said.
Source: Augusta Chronicle, The
Related Articles
- U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS
- Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
- Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program'
- U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program
- Mymetics Announces Encouraging Preclinical Results of the Company's HIV Vaccine Candidate in Non-Human Primates
- Biovitrum Creates iNovacia, The Nordic Region's Largest Contract Research Company in Early Drug Discovery
- Africa: Former U.N. HIV/AIDS Chief Says Prevention Efforts Failed
- White House Partnership on Pediatric HIV/AIDS a Positive Development, Says Global AIDS Alliance
- The Uganda Virus Research Institute (UVRI), in Collaboration With the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics, Launches HIV/AIDS Vaccine Trial in Entebbe, Uganda
- HIV, AIDS Patients Wait for Drug Funding
User Comments (0)

RSS Feeds